Epizyme's sarcoma drug tazemetostat faces key vote from FDA ...

Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.

Xtandi catches up with Erleada in castration-sensitive prost...

BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).

GSK files multiple myeloma drug with FDA after phase 2 succe...

GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results fr

Trial answers the KRAS question for Keytruda in lung cancer

AZ's Imfinzi approved in early lung cancer in China

The Chinese regulator has approved AstraZeneca’s Imfinzi in an early form of lung cancer after treatment with chemotherapy and radiation.